Table 2.
Demographic and baseline characteristics of the patient population.
| Characteristics | Acupuncture group (n = 33) | Sham group (n = 33) | Total (n = 66) |
|---|---|---|---|
| Gender (male), n (%) | 20 (60·6) | 21 (63·6) | 41(62·1) |
| Age (years), mean (SD) | 39·5 (15·0) | 41·3 (13·5) | 40·4(14·2) |
| Height (cm), mean (SD) | 168·1 (7·4) | 168·2 (8·3) | 168·2(7·8) |
| Weight (kg), mean (SD) | 53·9 (8·1) | 54·8 (10·5) | 54·3(9·3) |
| BMI (kg/m2), mean (SD) | 19·1 (2·5) | 19·3 (2·8) | 19·2(2·7) |
| Ethnicity (Han Chinese), n (%) | 33 (100·0) | 33 (100·0) | 66(100·0) |
| Duration of CD (months), mean (SD) | 41·4 (35·9) | 42·4 (33·8) | 41·9(34·6) |
| The Montreal classification, n (%) | |||
| A1 | 1 (3·0) | 3 (9·1) | 4(6·1) |
| A2 | 19 (57·6) | 19 (57·6) | 38(57·6) |
| A3 | 13 (39·4) | 11 (33·3) | 24(36·4) |
| L1 | 11 (33·3) | 12 (36·4) | 23(34·8) |
| L2 | 6 (18·2) | 6 (18·2) | 12(18·2) |
| L3 | 16 (48·5) | 15 (45·5) | 31(47·0) |
| B1 | 22 (66·7) | 17 (51·5) | 39(59·1) |
| B2 | 6 (18·2) | 13 (39·4) | 19(28·8) |
| B3 | 5 (15·2) | 3 (9·1) | 8(12·1) |
| B1p | 7 (21·2) | 10 (30·3) | 17(25·8) |
| B2p | 2 (6·1) | 4 (12·1) | 6(9·1) |
| B3p | 1 (3·0) | 1 (3·0) | 2(3·0) |
| Concomitant medication, n (%) | 26 (78·8) | 27 (81·8) | 53(80·3) |
| Glucocorticoid (prednisone) | 9 (27·3) | 5 (15·2) | 14(21·2) |
| 5-ASA | 12 (36·4) | 17 (51·5) | 29(43·9) |
| AZA | 12 (36·4) | 9 (27·3) | 21(31·8) |
| MTX | 1 (3·0) | 3 (9·1) | 4(6·1) |
| Surgical history, n (%) | 10 (30·3) | 14 (42·4) | 24(36·4) |
| CDAI, mean (SD) | 211·3 (52·2) | 206·0 (45·1) | 208·7(48·4) |
| CDAI > 220, n (%) | 13 (39·4) | 14 (42·4) | 27(40·9) |
| CRP (mg/L), mean (SD) | 14·8 (16·5) | 12·7 (15·7) | 13·8(16·0) |
| CDEIS, mean (SD) | 9·2 (4·9) | 9·5 (5·2) | 9·3 (5·0) |
| Ulcers of small intestine, n (%)a | 15 (56·6) (n = 27) | 14 (51·9) (n = 27) | 29(53·7) (n = 54) |
| Edema of small intestine, n (%)a | 20 (74·1) (n = 27) | 21 (77·8) (n = 27) | 41(75·9) (n = 54) |
| FC (µg/g), mean (SD) | 560·1(159·4) (n = 15) | 534·4(173·7) (n = 15) | 547·2(164·3) (n = 30) |
NOTE: 5-ASA, 5-aminosalicylicacid; A1, age > 17; A2, age 17–40; A3, age < 40; AZA, Azathioprine; B1, non-structuring and non-penetrating; B2, structuring; B3, penetrating; BMI, body mass index; CD, Crohn's Disease; CDAI, Crohn's Disease Activity Index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein; FC, fecal calprotectin; L1, ileal; L2, colonic; L3, ileocolic; MTX, Methotrexate; P, Perianal disease; SD, standard deviation.
a
Sum of L1 and L3.